Your browser doesn't support javascript.
loading
Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.
Pernot, Simon; Pellerin, Olivier; Mineur, Laurent; Monterymard, Carole; Smith, Denis; Lapuyade, Bruno; Gallois, Claire; Khemissa Akouz, Faiza; De Baere, Thierry; Tougeron, David; Thirot-Bidault, Anne; Audemar, Franck; Simon, Mireille; Lecaille, Cedric; Louafi, Sami; Lepage, Come; Ducreux, Michel; Taieb, Julien.
Afiliação
  • Pernot S; Department of Medical Oncology, Institut Bergonié, Bordeaux, France. Electronic address: Simon.pernot@gmail.com.
  • Pellerin O; Department of Interventional Radiology, Hopital Européen Georges-Pompidou, Université de Paris, SIRIC CARPEM, France.
  • Mineur L; Department of Medical Oncology, Institut Sainte Catherine, Avignon, France.
  • Monterymard C; Federation Francophone de Cancérologie Digestive (FFCD), EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France.
  • Smith D; Department of Gastroenterology and GI Oncology, CHU Haut-Leveque, Université de Bordeaux, Pessac, France.
  • Lapuyade B; Department of Interventional Radiology, CHU Haut-Leveque, Université de Bordeaux, Pessac, France.
  • Gallois C; Department of Gastroenterology and GI Oncology, Hopital Européen Georges-Pompidou, Université de Paris, SIRIC CARPEM, France.
  • Khemissa Akouz F; Department of Gastroenterology and GI Oncology, CH Saint-Jean, Perpignan, France.
  • De Baere T; Department of Interventional Radiology, Gustave Roussy, BIOTHERIS, Université Paris-Saclay, Villejuif, France.
  • Tougeron D; Université de Poitiers, Department of Gastroenterology and Hepatology, CHU La Milétrie, Poitiers, France.
  • Thirot-Bidault A; Department of Medical Oncology, Hôpital Privé d'Antony, Antony, France.
  • Audemar F; Department of Gastroenterology and GI Oncology, CH de la Côte-Basque, Bayonne, France.
  • Simon M; Department of Gastroenterology and GI Oncology, CH Pau, Pau, France.
  • Lecaille C; Department of Gastroenterology and GI Oncology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.
  • Louafi S; Department of Medical Oncology, CH Corbeille Essonne, France.
  • Lepage C; Federation Francophone de Cancérologie Digestive (FFCD), EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, Dijon, France; Department of Gastroenterology and GI Oncology, CHU Haut-Leveque, Université de Bordeaux, Pessac, France; Department of Interventional Radiology, CHU Haut-Lev
  • Ducreux M; Department of Medical Oncology, Gustave Roussy, Inserm U1279, Université Paris-Saclay, Villejuif, France.
  • Taieb J; Department of Gastroenterology and GI Oncology, Hopital Européen Georges-Pompidou, Université de Paris, SIRIC CARPEM, France.
Dig Liver Dis ; 54(3): 324-330, 2022 Mar.
Article em En | MEDLINE | ID: mdl-35027324
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Bevacizumab / Oxaliplatina / Neoplasias Hepáticas Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Dig Liver Dis Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Bevacizumab / Oxaliplatina / Neoplasias Hepáticas Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Dig Liver Dis Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2022 Tipo de documento: Article